Trial
NCT01484860
Study of AUY922 in Metastatic Pancreatic Cancer Who Are Resistant to First Line Chemotherapy
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
University Health Network, Toronto
Collaborators
Novartis Pharmaceuticals
Condition
Adenocarcinoma of the Pancreas
Intervention
AUY922
Why stopped
—
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-02-15